Kornimate/medical-research-clean huggingface dataset:
ct coronary angiography after arterial switch operation

Conditions: CT Coronary Angiography; Arterial Switch Operation

Summary: the purpose of this study is to find a non-invasive alternative (with using ecg gated 64-slice ct angiography) to invasive coronary angiography for detecting coronary lesions in patients who had undergone arterial switch operation for transposition of the great arteries

objectives to find a non-invasive alternative (with using ecg-gated 64-slice ct angiography) to invasive coronary angiography for detecting coronary lesions in children who had undergone arterial switch operation for transposition of the great arteries. background assessment of the integrity of reimplanted coronary arteries is crucial for long-term outcome after arterial switch operation for transposition of the great arteries. non-invasive tests have limited accuracy for detecting coronary lesions, and invasive coronary angiography is usually required in this setting. materials and methods patients (age 4 to 30 years old) who undergone arterial switch operation in neonate period are potentially eligible. they will be prospectively included in the study. they will have both examinations, their routine invasive coronary angiography and ecg-gated 64-slice ct angiography. the ability of ct to detect lesions of the ostia and proximal segments of the reimplanted coronary arteries was analyzed by blinded comparison to invasive coronary angiogram. expected results and clinical implications we expect to demonstrate that ecg-gated 64-slice ct angiography is safe and accurate for the detection of coronary lesions with a high sensitivity (expected sensitivity\>95%) as compared to invasive angiography. in that condition, ecg-gated 64-slice ct angiography could replace the invasive coronary angiography for the follow-up of patients with reimplanted coronary arteries after arterial switch operation for transposition of the great arteries.

Eligibility criteria:
inclusion criteria : * patients, age 4 to 30 years old, who had undergone arterial switch operation for transposition of the great arteries, are eligible. exclusion criteria : * no consent * allergy to contrast agent (iodine contrast) * severe renal failure (clearance \< 80ml/min/1.73m²) * severe arrhythmias * absence of medical care insurance * pregnancy * contre-indication to beta-blockers

Keywords: arterial switch operation transposition of the great arteries congenital heart diseases ct coronary angiography
improving functioning in persons with chronic pain post-sci through virtual classroom education

Conditions: Chronic Pain; Spinal Cord Injuries

Summary: chronic pain (pain that is that is present for a long period of time) is very common among people with spinal cord injury (sci). the purpose of this study is to compare how well two different web-based education programs reduce the level to which chronic pain interferes with daily activities and well-being.

chronic pain (pain that is present for a long period of time) is common among people with spinal cord injury (sci). the pain is often severe and can affect daily activities. unfortunately, common treatments such as medications provide incomplete relief from chronic pain. thus, persons with sci have to find alternate ways to live a happy, healthy, and productive life, even with some pain. the purpose of this study is to compare how well two different web-based education programs reduce the level to which chronic pain interferes with daily activities and well-being.

Eligibility criteria:
inclusion criteria: * sci for at least one year * chronic pain for at least three months that is moderate to severe * fluent in english * not currently starting a new pain treatment or changing a previous pain treatment exclusion criteria: * lack of access to a computer with high-speed internet access, at home or another location * cancer or conditions that may worsen over time (such as multiple sclerosis, parkinson disease, alzheimer's disease) and may affect physical or mental functioning * significant difficulties with learning or memory * previous participation in a health and function education program specifically designed for people with chronic pain and sci * inability to understand english well * other conditions not related to sci that cause pain (such as fibromyalgia)

Keywords: mindfulness spinal cord injury
global secondary prevention strategies to limit event recurrence after myocardial infarction. gospel study

Conditions: Myocardial Infarction

Summary: cardiac rehabilitation programmes are a proven treatment for individuals with recent myocardial infarction, resulting in reduced morbidity and mortality compared to usual care. unfortunately, following completion of a cardiac rehabilitation programme, risk factors and lifestyle behaviours may deteriorate. the gospel study investigates the benefits of a programme of continued educational and behavioural intervention to achieve optimal long-term secondary prevention goals.

study partially sponsored by società prodotti antibiotici

Eligibility criteria:
inclusion criteria: * recent myocardial infarction (within 3 months after the index event) * standard rehabilitation program of 3-6 weeks performed * informed consent (obtained before any study specific procedure) exclusion criteria: * age \> 75 years * any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or be associated with poor adherence to the protocol; * presence of any non-cardiac disease (e.g. cancer) that is likely to significantly shorten life expectancy

Keywords: cardiac rehabilitation lifestyle management risk factor management myocardial infarction randomized trials
interleukin-1 receptor antagonist and insulin sensitivity

Conditions: Diabetes Mellitus, Type 2; Insulin Resistance

Summary: obesity is characterized by continuous low-grade inflammation. this is an important link between obesity and insulin resistance. results from the investigators' own group of in vitro and in vivo research on mice show that interleukin-1 is involved in the process of developing insulin resistance. earlier it has been shown that interleukin-1 receptor antagonist in human subjects improves glycemic control. the investigators' hypothesis is that this is due to improved insulin sensitivity.

the prevalence of obesity is increasing fast. obesity is one of the most common acquired risk factors for insulin resistance. as a consequence the prevalence of type 2 diabetes mellitus is rising fast as well. interleukin 6 and tumor necrosis factor alfa are well known pro-inflammatory cytokines that have been linked to insulin resistance. results from our own group show that interleukin-1 is also involved in the process of developing insulin resistance. earlier research projects studied the effect of interleukin-1 receptor antagonist (anakinra) on glycemic control in subjects with type 2 diabetes mellitus. it was shown that glycemic control was improved. the authors conclude that this is the result of improved function of pancreatic beta cells. these results are in contrast to our results of in vitro en in vivo research on mice, which show improved insulin sensitivity by interleukin-1 receptor antagonist. a possible explanation for not finding an effect on insulin sensitivity by earlier research projects may be that it is difficult to reliable quantify insulin sensitivity in this group of patients with concurrent changes in glycemic control, extensive co-morbidity and medication use, who might be at the rather extreme end of insulin resistance. furthermore a relatively low dose of anakinra was used. altogether we hypothesize that the effect of interleukin-1 is not only mediated through better pancreatic beta-cell function, but that interleukin-1 blocking by recombinant interleukin-1 receptor antagonist will also diminish insulin resistance.

Eligibility criteria:
inclusion criteria: * adult subjects with a bmi \> 30 kg/m2 * 3 or more characteristics of the metabolic syndrome exclusion criteria: * inability to give informed consent * age \< 18 years * known diabetes mellitus * fasting plasma glucose \> 7,0 mmol/l or hba1c \> 6,2% * presence of any medical condition that might interfere with the current study protocol * immunodeficiency of immunosuppressive treatment * anti-inflammatory drugs (100 mg of aspirin/day is allowed) * signs of current infection * history of recurrent infections * pregnancy or breast feeding * liver disease * renal disease * neutropenia

Keywords: anakinra diabetes mellitus, type 2 insulin resistance interleukin-1beta
comparison of gait parameters between floor and sponge surfaces and special shoes

Conditions: Arthroscopic Knee Surgery; Lower Limb Fractures; Back Pain and Asymmetric Gait; Complex Regional Pain Syndrome

Summary: this study compares the gait pattern of individuals with weight bearing difficulties walking on the floor, a soft surface, or with special shoes (kyboot).


Eligibility criteria:
inclusion criteria: * 3 days to 1 month following arthroscopic knee surgery(n=10) * following fractures in lower limb with pain during weight-bearing (n=10) * back pain and asymmetrical gait (n=10) * complex regional pain syndrome with pain during weight-bearing (n=10) exclusion criteria: * neurological condition that does not permit walking on soft surface (drop foot) * wounds on feet
comparison of two different dosages of low-molecular weight heparin in cancer patients

Conditions: Cancer

Summary: in a prospective, randomized, double-blind trial, the effects of two different dosages of lmwh (5000 anti-xa u od sc and 10 000 anti-xa u od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.


Eligibility criteria:
inclusion criteria: patients (\> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with lmwh: * immobilization * history of vte * acute inflammation * heart failure (nyha class iii or iv) * respiratory failure exclusion criteria: * indication for lmwh or ufh at therapeutic dosages * treatment with antithrombotics (vitamin k antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of vte (e.g. atrial fibrillation, myocardial infarction) * contraindication for the treatment with lmwh * major surgery within the last 4 weeks; minor surgery within the last week * thrombocytopenia (\< 100.000/μl) * prolonged prothrombin time * prolonged activated partial thromboplastin time (aptt) * history of heparin-induced thrombocytopenia * bodyweight \ 100 kg * renal insufficiency (creatinine \> 2 mg/dl)
effect of different pastes on remineralization of early caries lesions in primary teeth

Conditions: White Spot Lesion of Tooth

Summary: this study is a randomized controlled trial involving 118 children ages between 4 and 5 years to assess the remineralization effect of casein phosphopeptide-amorphous calcium phosphate (cpp-acp) on white spot lesions in primary teeth using quantitative light-induced fluorescence (qlf) system, and compare that with fluoride alone or combined use of fluoride and cpp-acp.

aim: to assess the remineralization effect of cpp-acp on white spot lesions in primary teeth using qlf system, and compare that with fluoride alone or combined use of fluoride and cpp-acp. materials and methods: o study design: the present study is a randomized control trial (rct). * study setting: the present study will be conducted at kindergartens, irbid, jordan. a list of schools will be obtained from the development sector, schools will be invited to be participate in the study. children will be randomly allocated into groups. * study procedure: * study population includes healthy children (n=118) aged between 4-5 years diagnosed with white spot lesions. * oral examination at baseline to record dmft and caries risk using the caries-risk assessment tool (cat) based on american academy of pediatric dentistry (aapd) guidelines will be carried out, patients will be classified as: low, moderate or high risk * quantitative assessment of early caries lesions will be carried out using qlf. * children will be randomly allocated into three groups: group 1: children will brush their teeth with cpp-acp twice daily. group 2: children will brush their teeth with fluoridated toothpaste twice daily. group 3: children will brush their teeth with fluoridated toothpaste and apply cpp-acp immediately after tooth brushing, twice daily. the researcher will do the morning application at school, the evening application will be done at home with help of the parent. the researcher will give oral hygiene and brushing instructions to the parents and also diet advice. an oral hygiene chart will be given to monitor twice-daily tooth brushing.

Eligibility criteria:
inclusion criteria: * healthy 4-5 years old children, with primary dentition, and early white spot lesions exclusion criteria: * lack of cooperation in the oral examination. * allergies to milk protein. * have received a fluoride supplement or professional topical fluoride application at least 3 months before or during the study period. * medically compromised patient.

Keywords: quantitative laser fluorescence (qlf) cpp-acp paste fluoride toothpaste combined use of fluoride and cpp-acp paste primary teeth
the effect of pancreatic polypeptide on insulin requirements for type 1 & post-pancreatectomy diabetic patients

Conditions: Diabetes Mellitus, Type 1

Summary: the goal of this research is to see if pancreatic polypeptide (pp), a hormone that is naturally produced by the pancreas and that works to control the amount of glucose that the liver makes, will reduce the amount of insulin required for people who must take insulin to maintain their normal blood glucose level.

the pancreas is a large gland located behind the stomach. one of the functions of the pancreas is to produce two hormones: insulin and pancreatic polypeptide. insulin helps the cells to take in glucose. the liver makes glucose and insulin normally acts to decrease or shut off the liver's production of glucose. however, in patients whose pancreas no longer makes insulin or makes low levels of pancreatic polypeptide the liver cannot perform these duties as well. studies have shown that these important functions of the liver are improved for these patients when pancreatic polypeptide is given together with their insulin. because pp increases the liver's sensitivity to insulin and thereby reduces the amount of glucose produced by the liver, this will result in fewer swings in blood sugar levels both in the upper and lower range. with fewer swings in blood glucose, a patient should decrease the amount of insulin used. one of the main benefits of lowering total insulin requirement is a reduction in the development of dangerous low blood sugar levels.

Eligibility criteria:
inclusion criteria: * male and female volunteers between the ages of 18-75 with: * 10 subjects who are status post pancreatic resection and 10 volunteers who are type 1 diabetic for \> 8 years (volunteers must have a stable glycemic profile that includes use of an insulin pump to control their blood glucose) with or without prior pancreatic resection. * hba1c levels ≤ 8.5. exclusion criteria: * lactating or pregnant females. * brittle or labile diabetics: volunteers with extremely erratic patterns of glucose control with large fluctuations in glucose levels for no obvious reason. * allergy to beef or beef by-products. * hypoglycemia within the past year requiring medical or other assistance to correct. * known autonomic neuropathy. * documented blood glucose under 60 mg within the past year and hypoglycemic unawareness. * durations of type 1 diabetes melitis (dm) ≤ 8 years. * not currently on pump therapy. * type 1 dm who has a bmi ≥ 35.

Keywords: insulin pump therapy type 1 diabetic chronic pancreatitis pancreatic resection pancreatic polypeptide
effect of exendin-(9-39) on fasting adaptation and protein sensitivity

Conditions: Congenital Hyperinsulinism

Summary: the purpose of this study is to examine the effects of exendin-(9-39) on fasting blood glucose and protein induced hypoglycemia on subjects with congenital hyperinsulinism. funding source - fda office of orphan products development (oodp).

this is a placebo controlled study with randomized crossover design to evaluate the effect of the glucagon-like peptide-1 (glp-1) receptor antagonist, exendin-(9-39), on fasting blood glucose levels, protein-induced hypoglycemia, and fasting tolerance of subjects with congenital hyperinsulinism due to mutations in the atp- sensitive potassium channel (katp) channel.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of hyperinsulinism * mutation analysis results demonstrating katp channel defect * age 6 months to 18 years with * persistent hypoglycemia exclusion criteria: * current therapy with medications that may affect glucose metabolism such as octreotide, diazoxide, high dose glucocorticoids, adrenergic agents, etc. subjects will be eligible to participate if the last dose of octreotide is given 48 hrs before study day 1 and the last dose of diazoxide is given 72 hours before study day 1 * evidence of a medical condition that might alter results or compromised the elimination of the peptide, including active infection, kidney failure, severe liver dysfunction, severe respiratory or cardiac failure * pregnancy * subjects with milk protein allergy will be excluded for participating in studies involving protein tolerance test

Keywords: hyperinsulinism hypoglycemia katp channel
sleep apnea treatment with expiratory resistance(provent™)

Conditions: Sleep Apnea, Obstructive

Summary: continuous positive airway pressure (cpap) continues to be the primary therapy prescribed for the treatment of obstructive sleep apnea (osa). although effective, adherence to cpap is suboptimal in many patients, making alternative therapies desirable. recently, a novel device (provent™) has been developed for the treatment of snoring and osa. the purpose of the current study is to examine how well the provent™ device treats osa with particular attention to the how the it may treat sleep apnea and who may most likely benefit from the use of this treatment.


Eligibility criteria:
inclusion criteria: * consenting adults over the age of 18 * diagnosed obstructive sleep apnea (defined as an rdi \> 5 events per hour \& ≥ 90% of disordered breathing events classified as obstructive) exclusion criteria: * total sleep time from previous sleep study \< 4 hours (240 minutes) * severe bilateral nasal obstruction (apparent mouth breathing at rest) * documented history of lung diseases, as defined below: * daytime hypercapnia (paco2 \> 45 mmhg) * baseline sao2 ≤ 92% * chronic lung disease except mild intermittent or mild persistent asthma * cor pulmonale * documented clinical cardiovascular disease, as defined below: * myocardial infarction in past 3 months * revascularization procedure in past 3 months * implanted cardiac pacemaker or icd * unstable arrhythmias * congestive heart failure with ejection fraction \< 40% * uncontrolled hypertension (bp \> 190/110) * history of end stage renal disease (on dialysis) * history of end stage liver disease, such as: * jaundice * ascites * history of recurrent gastrointestinal bleeding * transjugular intrahepatic portosystemic shunt (tips) ; * sleep disorders other than obstructive sleep apnea, such as: * narcolepsy * restless leg syndrome * periodic limb movements causing an arousal index of \> 5 per hour * transportation industry worker (commercial truck or bus drivers, airline pilots) * known pregnancy (by self report) * known coagulopathy or anticoagulant use (e.g. coumadin) other than aspirin. * allergy to lidocaine

Keywords: sleep apnea treatment collapsibility expiratory nasal resistance
vibraimage technology for detecting depression in psychiatric outpatients

Conditions: Depression

Summary: vibraimage technology captures high-frame-rate images of head-neck movements, converting them into vibraimages that display muscle vibration amplitude and frequency. using algorithms and calculations, it derives an emotional index from these images. this non-contact, objective method analyzes psychological indicators through micro-movement detection. an algorithm has been developed to detect depression by calculating 12 emotional and 2 psychophysiological parameters. this diagnostic accuracy study aims to validate the technology's ability to diagnose depression in psychiatric outpatients.


Eligibility criteria:
inclusion criteria: * aged 18 to 70 years. * no difficulties in reading or writing chinese; fluent in mandarin. * currently not taking psychotropic medications or on a stable dose for at least 6 weeks. * provided informed consent to participate in the study. exclusion criteria: * schizophrenia. * bipolar disorder. * history of organic brain disease or significant head trauma. * presence of severe systemic medical conditions. * suicidal ideation or a score ≥3 on item 3 ("suicide") of the 17-item hamilton depression rating scale (hamd-17). * substance dependence or abuse. * intellectual disability or dementia. * inability to complete video capture or cooperate due to uncontrollable factors (e.g., hyperactivity, parkinson's disease, or other conditions that prevent remaining still)
alemtuzumab in treating patients with advanced chronic lymphocytic leukemia that did not respond to previous fludarabine

Conditions: Leukemia

Summary: rationale: monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. some block the ability of cancer cells to grow and spread. others find cancer cells and help kill them or carry cancer-killing substances to them. purpose: this phase ii trial is studying how well giving alemtuzumab by injection works in treating patients with advanced chronic lymphocytic leukemia that did not respond to previous fludarabine.

objectives: * compare the safety and efficacy of subcutaneous alemtuzumab vs intravenous alemtuzumab in patients with fludarabine-refractory advanced chronic lymphocytic leukemia. * determine the response in patients with high-risk genetic abnormalities (unmutated immunoglobulin variable heavy-chain \[igvh\] status, del \[17p\], del \[11q\]) treated with subcutaneous alemtuzumab after progression on fludarabine. outline: this is a multicenter study. patients receive alemtuzumab iv once, followed 1 week later by alemtuzumab subcutaneously once weekly for up to 12 weeks. projected accrual: a total of 100 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * confirmed diagnosis of previously treated advanced chronic lymphocytic leukemia (cll) * fludarabine-refractory disease * requires treatment patient characteristics: * life expectancy more than 6 months * ecog 0-2 * no severe organ dysfunction * no other concomitant or previous neoplasms * no autoimmune hemolytic anemia or thrombocytopenia prior concurrent therapy: * see disease characteristics * up to 5 prior chemotherapy regimens allowed

Keywords: refractory chronic lymphocytic leukemia stage iii chronic lymphocytic leukemia stage iv chronic lymphocytic leukemia